ECSTASY FOR BIG PHARMA –
Dec. 14, 2023 – The biotech company MAPS Public Benefit Corporation (MAPS PBC) is a step closer to official approval for its MDMA-based therapy that supposedly treats post-traumatic stress disorder (PTSD). If approved, MDMA would then have to be rescheduled so it can be available as a prescription medication.
The proposed therapy uses “a combination of MDMA, psychotherapy (also known as talk therapy) and other supportive services to treat PTSD,” the release stated. A 2021 meta-analysis in the Journal of Clinical Pharmacology found that although “MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks.”
